Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06433609

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Sponsor: Beijing GoBroad Hospital

Interventions Adebrelimab SHR-A1811 SHR-A1921

Updated 3 times since 2024 Last updated: May 28, 2024 Started: Jun 30, 2024 Primary completion: Jul 31, 2027 Completion: Nov 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Beijing GoBroad Hospital and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing GoBroad Hospital

Data source: Beijing GoBroad Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China